Orbital Therapeutics Strengthens Leadership with the Appointment of Biopharma Veteran Geno Germano to Its Board of Directors Orbital Therapeutics, a pioneering biotechnology company focused on advancing RNA-based medicines to address a wide range of diseases, has announced the appointment of…
Leading Cancer Center Adopts Abridge AI for Oncology Documentation Abridge, a leader in AI-driven clinical documentation solutions, has announced an extensive rollout of its AI platform at Memorial Sloan Kettering Cancer Center (MSK). This deployment, set to take place throughout…
Estrella Immunopharma Receives Buy Rating from CB Capital Partners with a $14.00 Price Target Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company pioneering the development of CD19 and CD22-targeted ARTEMIS® T-cell therapies for cancer and…
LEO Pharma Survey: Chronic Hand Eczema Misunderstood and Undermanaged LEO Pharma Survey Highlights Widespread Misunderstanding and Inadequate Management of Chronic Hand Eczema Among Dermatology Providers A recent survey commissioned by LEO Pharma Inc., a global leader in medical dermatology, and…
GeneDx Expands Exome and Genome Testing Access, Adding Cerebral Palsy as a New Indication GeneDx (Nasdaq: WGS), a leading innovator in genomic insights, has announced an expansion of its genetic testing services to include cerebral palsy (CP) as an indication.…
Epredia Secures FDA 510(k) Clearance for E1000 Dx™ Digital Pathology Solution Epredia, a global leader in precision cancer diagnostics and a subsidiary of PHC Holdings Corporation (TSE: 6523), has announced that it has received U.S. Food and Drug Administration (FDA)…
Repligen Acquires 908 Devices’ Bioprocessing Analytics Portfolio for $70 Million Repligen Corporation (Nasdaq: RGEN), a leading life sciences company specializing in bioprocessing technology, has announced the acquisition of 908 Devices Inc.’s (Nasdaq: MASS) desktop portfolio, further strengthening its position in…
FDA Grants Orphan & Rare Pediatric Status to NEU-001 for Hirschsprung Disease Neurenati Therapeutics Inc., a biotechnology company specializing in rare pediatric diseases, has announced a significant regulatory milestone. The U.S. Food and Drug Administration (FDA) has granted both Orphan…
Amylyx Reports Q4 and Full-Year 2024 Financial Results Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) recently released its financial results for the fourth quarter and full year ending December 31, 2024, showcasing significant advancements in its research and…
TEVIMBRA Gains U.S. Approval for First-Line Esophageal Cancer Treatment with Chemotherapy BeiGene, Ltd. a global oncology company that has announced its intent to change its name to BeOne Medicines Ltd., recently revealed that the U.S. Food and Drug Administration (FDA)…
FairJourney Biologics Acquires Charles River’s South San Francisco Site FairJourney Biologics S.A., a global leader in antibody discovery and optimization, has announced the successful acquisition of the South San Francisco site from Charles River Laboratories International, Inc. This strategic acquisition…
Surescripts 2024 Annual Impact Report Highlights Surge in Health Intelligence Sharing, Enhancing Care Quality & Access Surescripts, the nation’s leading health information network, has released its highly anticipated 2024 Annual Impact Report, underscoring the transformative advancements in health intelligence sharing.…